English

Interim report January – September 2021: Profitable growth and Igenomix acquisition

Report this content

Third quarter:

  • Sales amounted to SEK 406 (320) million, corresponding to an increase of 27 percent in SEK. Sales increased by 30 percent in local currency.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 162 (134) million, corresponding to a margin of 40 (42) percent. Currency effects positively impacted EBITDA by SEK 1 million. Operating income included non-recurring acquisition-related costs of SEK 8 million. Adjusted EBITDA therefore amounted to SEK 170 million, corresponding to a margin of 42 percent.
  • Net income amounted to SEK 105 (89) million, which gave earnings per share of SEK 0.89 (0.81).
  • Vitrolife entered into an agreement to acquire 100% of the shares in Igenomix for a purchase sum of EUR 1.25 billion (approximately SEK 12.7 billion). During the quarter a directed share issue of SEK 3.6 billion was carried out as part-financing of the acquisition.

January - September:

  • Sales amounted to SEK 1 167 (863) million, corresponding to an increase of 35 percent in SEK. Sales increased by 41 percent in local currency.
  • EBITDA amounted to SEK 460 (290) million, corresponding to a margin of 39 (34) percent. Currency effects negatively impacted EBITDA by SEK 24 million. Operating income included non-recurring acquisition-related costs of SEK 22 million and non-recurring transport-related costs of SEK 3 million. Adjusted EBITDA therefore amounted to SEK 485 million, corresponding to a margin of 42 percent.
  • Net income amounted to SEK 310 (180) million, which gave earnings per share of SEK 2.77 (1.65).

After the end of the period:

  • An Extraordinary General Meeting resolved to approve the Board’s proposal regarding a non-cash issue of shares for SEK 6.4 billion as part-financing of the acquisition of Igenomix.
  • Patrik Tolf has been appointed new CFO of Vitrolife AB (publ) effective 1 January 2022.

Gothenburg, October 29, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on October 29, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Subscribe

Documents & Links